Patent intelligence · US
US 9422522
Method of producing adipocytes from fibroblast cells
Method of producing adipocytes from fibroblast cells
Patent details — US 9422522
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 23, 2016
- Expiration
- Aug 18, 2036
- Applicant
- Regenertech Pty Limited
- Claims
- 13
- CPC classes
- A61K, A61K35/12, A61P, A61P17/02
Quick answer
US 9422522 (Method of producing adipocytes from fibroblast cells) is held by Regenertech Pty Limited. Status: granted. Granted Aug 23, 2016. Expires Aug 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Regenertech Pty Limited
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K35/12, A61P, A61P17/02, A61P19/02, A61P3/10
More from Regenertech Pty Limited
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9422522?
US 9422522 (Method of producing adipocytes from fibroblast cells) is held by Regenertech Pty Limited. Status: granted. Granted Aug 23, 2016. Expires Aug 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9422522?
Regenertech Pty Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9422522 expire?
Our index shows an expiration date of Aug 18, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.